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An elevated vancomycin MIC is associated with poor outcomes in Staphylococcus aureus bacteremia (SAB) and is reported in
patients with methicillin-susceptible S. aureus (MSSA) bacteremia in the absence of vancomycin treatment. Here, using DNA
microarray and phenotype analysis, we investigated the genetic predictors and accessory gene regulator (agr) function and their
relationship with elevated vancomycinMIC using blood culture isolates from amulticenter binational cohort of patients with
SAB. Specific clonal complexes were associated with elevated (clonal complex 8 [CC8] [P< 0.001]) or low (CC22 [P< 0.001],
CC88 [P< 0.001], and CC188 [P 0.002]) vancomycinMIC. agr dysfunction (P 0.014) or agr genotype II (P 0.043) were
also associated with an elevated vancomycinMIC. Specific resistance and virulence genes were also linked to an elevated vanco-
mycinMIC, including blaZ (P 0.002), sea (P< 0.001), clfA (P< 0.001), splA (P 0.001), and the arginine catabolic mobile
element (ACME) locus (P 0.02). These data suggest that inherent organism characteristics may explain the link between ele-
vated vancomycinMICs and poor outcomes in patients with SAB, regardless of the antibiotic treatment received. A consider-
ation of clonal specificity should be included in future research when attempting to ascertain treatment effects or clinical
outcomes.
Multiple factors have been implicated in patients with pooroutcomes from Staphylococcus aureus bacteremia (SAB), in-
cluding treatment with vancomycin, particularly in methicillin-
susceptible S. aureus (MSSA) bacteremia (1–4). Elevated vanco-
mycin MIC has also been associated with treatment failure and
mortality in a recent meta-analysis of methicillin-resistant S. au-
reus (MRSA) infections (5). We previously reported an associa-
tion between elevated vancomycin MIC and 30-day mortality in
patients with SAB (6). Interestingly, this association was observed
even in patients with MSSA bacteremia treated with flucloxacillin,
a finding also noted by other authors (7); this persisted despite
adjustment for potential clinical confounders (8). Preliminary
data on a small subset of our original cohort demonstrated a het-
erogeneity of genotypes among MSSA and methicillin-resistant S.
aureus (MRSA) isolates and those with low or elevated vancomy-
cin MICs (6). However, specific organism characteristics, such as
resistance or virulence determinants and accessory gene regulator
(agr) type or function, are increasingly linked with elevated van-
comycin MIC. For example, MRSA strains with staphylococcal
cassette chromosome mec element (SCCmec) types II/III typically
have higher vancomycin MICs than strains with SCCmec types
IV/V (9). agr type II has been associated with reduced vancomycin
susceptibility (10), even in MSSA (11), and agr dysfunction has
been associated with mortality (12) and other suboptimal out-
comes (13). Specific genotypes have also been associated with el-
evated vancomycin MIC, such as non-CC22/30 clones in a study
of MRSA bacteremia (14), or infection syndromes that have in-
creased mortality, such as endocarditis or other invasive disease
(14–16). Other organism characteristics, such as the presence of
specific enterotoxins and adhesins, have been implicated in inva-
sive infection and may potentially influence clinical outcomes
(15).
We therefore performed a detailed microbial genetic charac-
terization on a subset of bacterial isolates from our original cohort
in order to identify links between organism factors and elevated
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vancomycin MIC that may in turn explain the increased mortality
observed.
(This study was presented in part at the 15th International
Symposium on Staphylococci and Staphylococcal Infections
[ISSSI], poster no. P 16-312, Lyon, France, 26 to 30 August 2012
[17].)
MATERIALS AND METHODS
Study population. The study population was derived from a prospec-
tively collected multicenter cohort of adult and pediatric patients with
SAB in Australia and New Zealand, the Australian and New Zealand Co-
operative on Outcomes in Staphylococcal Sepsis (ANZCOSS) (4). A sub-
study was previously created from eight geographically diverse hospitals
that contributed to this collaboration, and additional clinical, microbio-
logical, and pharmacological data were collected (6, 8). In brief, basic
demographics from the initial cohort and detailed microbiologic testing
of stored blood culture isolates (6) were combined with extended clinical
data that analyzed detailed comorbidities, comorbidity burden using the
Charlson comorbidity index, and disease severity scores using the Acute
Physiology and Chronic Health Evaluation (APACHE) II, Simplified
Acute Physiology Score (SAPS), and Pitt bacteremia scores (8) measured
within 24 h of SAB onset.
Selection of bacterial isolates. The first (index) positive blood culture
isolate from each patient in our original substudy was stored at 80°C,
and vancomycin MICs using broth microdilution (BMD) and Etest were
performed previously (6). Only isolates collected from patients for whom
expanded clinical data were available were considered for inclusion in this
analysis. We deliberately selected all blood culture isolates with very low
vancomycin Etest MICs (0.38 to 0.75 mg/liter, n  15) and very high
vancomycin Etest MICs (2.0 to 3.0 mg/liter, n 134) for further charac-
terization. The remaining isolates (n 93) comprised randomly selected
isolates with a vancomycin Etest MIC of 1.0 to 1.5 mg/liter.
Outcome measures. The primary outcome was vancomycin Etest
MIC, categorized into low (1.5 mg/liter) or elevated (1.5 mg/liter)
groups, as defined by our previous findings (6). Secondary outcomes in-
cluded persistent bacteremia (defined as blood cultures positive for S.
aureus taken 7 days after the index positive blood culture), and recur-
rent bacteremia (defined as a new episode of SAB after having docu-
mented negative blood cultures occurring within 30 days of the index
positive blood culture) (18).
Delta-hemolysin assay for agr function. The S. aureus accessory gene
regulator (agr) activity was measured by delta-hemolysin production on
Trypticase soy agar with 5% sheep blood using S. aureus strain RN4220, as
previously described (13, 19, 20). Evidence of enhanced hemolysis be-
tween RN4220 and a test isolate was considered positive for delta-hemo-
lysin production (20). The presence of agr dysfunction was defined as an
absence or severe depression of delta-hemolysin production (21). The
positive control was JKD6159, a fully sequenced S. aureus reference isolate
known to have a functional agr operon, and the negative control was
TPS3105, a sequenced S. aureus isolate with defective agr function (22).
DNA microarray. The isolates were characterized using the Staphy-
Type S. aureus DNA microarray (Alere Technologies, Jena, Germany).
This microarray detects 334 target sequences from 185 genes and allelic
variants, including resistance determinants and pathogenicity markers,
and it infers the genotype according to clonal complex (CC) or sequence
type (ST). The microarray was performed as per the manufacturer’s in-
structions, with the arrays and reagents obtained from Alere (11, 23–25).
Genotyping. A phylogram was constructed with the microarray data
using SplitsTree version 4.13.1 (26). The tree was constructed as an un-
rooted tree without any reference isolates in order to visualize the repre-
sented genotypes, and no inference of phylogenetic evolutionary direction
was made.
Statistical analysis. Statistical analyses were performed using Stata
version 11.1 (StataCorp, College Station, TX, USA). Categorical variables
were compared using the 2 test or Fisher’s exact test, while the Mann-
Whitney U test was used for continuous variables. A P value of0.05 was
considered to be statistically significant. Statistical corrections for multi-
ple comparisons were not performed, as this was a hypothesis-generating
study to ascertain possible organism characteristics.
Ethics. Human ethics committee approval was obtained at each par-
ticipating site.
RESULTS
Clinical characteristics. Two hundred forty-two isolates were
tested, representing almost half (45.5%) of the 532 isolates col-
lected from the original multicenter cohort. The demographics of
the tested patient population (Table 1) revealed no statistically
significant differences between patients in the low- or elevated-
vancomycin MIC groups. There were no differences between the
vancomycin MIC group and common clinical manifestations.
The proportion of MRSA was overrepresented in the elevated-
vancomycin MIC group compared with the low-vancomycin MIC
group (52.2% versus 31.5%, P 0.001).
Genotype.There were 25 different CCs among the 242 isolates.
The DNA microarray was unable to assign a CC for one isolate.
Greater clonal diversity was noted among the MSSA isolates than
with the MRSA isolates (24 versus 10, respectively). Figure 1 shows
the unrooted phylogenetic relationship between the isolates. CC8
was the most common genotype (n 69), followed by CC5 (n
26), CC22 (n  20), CC45 (n  18), and CC30 (n  15). The
isolate with an unassigned CC on the microarray clustered phylo-
genetically with the CC188 isolates. Two isolates clustered within
the livestock-associated S. aureus CC398 (ST398 and ST291).
There were differences in the vancomycin MIC groups according
to CC (Fig. 2), with seven CCs having a geometric mean vanco-
mycin MIC of 1.5 mg/liter (CC8, CC15, CC6, CC5, CC20,
CC45, and CC1). Table 1 also identifies specific clones associated
with low (CC22, CC88, and CC188) or elevated vancomycin MICs
(CC8 and CC5), and Table 2 shows the vancomycin MIC values
for the more common clonal complexes. Clones with higher geo-
metric mean vancomycin MICs also had higher MIC50s and
MIC90s (see Fig. S1 in the supplemental material). Notably, CC22
was predominantly composed of ST22-MRSA-IV (known as epi-
demic MRSA [EMRSA]-15) (19/20) and was exclusively associ-
ated with a low vancomycin MIC. CC22 was also negatively associ-
ated with persistent bacteremia (P  0.020). The majority of the
isolates within CC8 were ST239-MRSA-III (60/69), an epidemic
health care-associated MRSA clone, most of which had elevated van-
comycin MIC. These ST239-MRSA-III isolates originated from five
different hospitals in diverse geographic regions in Australia and New
Zealand. Staphylococcal chromosomal cassette (SCC)mec type II/III
was associated with a high vancomycin MIC (P  0.001) and was
exclusively found in the isolates from CC8, whereas SCCmec type
IV/V was associated with a low vancomycin MIC (P  0.001) and
predominantly comprised ST22-MRSA-IV isolates. CC8 was associ-
ated not only with a high vancomycin MIC (Table 1) but also persis-
tent bacteremia (8/13, P 0.014), recurrent bacteremia (9/17, P
0.025), and sepsis syndrome (P 0.04). CC188, a clone with a low
vancomycin MIC, was associated with reduced 30-day mortality (0/
72, P 0.026) and community-onset infections (10/120, P 0.005)
and it comprised MSSA only. There were 11 different clones that
caused endocarditis, and no single clone predominated.
agr dysfunction. agr dysfunction was detected in more than
half of the isolates (124/242 [51.2%]), with high rates in agr type
III (34/48 [70.83%], P  0.002) and lower rates in agr type II
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TABLE 1 Demographics and clinical features of patients with SAB and microbial characterization of bacterial isolates according to low versus
elevated vancomycin MIC
Variablea Low MIC (n 108) Elevated MIC (n 134) P valueb
Demographics
Age (median [IQR]) (yr) 64 (44.5–77.5) 67.5 (50–76) 0.886
Male sex 81 (75.0) 91 (67.9) 0.227
Caucasian ethnicity 91 (84.3) 110 (82.1) 0.655
Hospital onset 48 (44.4) 74 (55.2) 0.095
Device-associated (no./total evaluablec [%]) 47/103 (45.6) 65/129 (50.4) 0.471
MRSA 34 (31.5) 70 (52.2) 0.001
Vancomycin treatment 51 (47.2) 79 (59.0) 0.069
Relapse (no./total infected [%]) 8/103 (7.77) 9/130 (6.9) 0.806
Persistent bacteremia (no./total evaluablec [%]) 5/82 (6.1) 8/115 (7.0) 0.811
Clinical features
DNR order (no./total evaluablec [%]) 34/95 (35.8) 51/122 (41.8) 0.368
ICU admission (no./total evaluablec [%]) 34/107 (31.8) 40/132 (30.3) 0.807
Infective endocarditis 8 (7.4) 8 (6.0) 0.655
Sepsis syndrome 14 (13.0) 18 (13.4) 0.915
Pneumonia 7 (6.5) 7 (5.2) 0.677
Osteoarticular 7 (6.5) 9 (6.7) 0.942
Skin and skin structure 13 (12.0) 23 (17.2) 0.265
Disease severity
APACHE II score (median [IQR]) 15 (10–19) 15.5 (11–20) 0.577
SAPS II score (median [IQR]) 26 (19–35) 27 (20–37) 0.354
Charlson comorbidity index (median [IQR]) 1 (0–2) 2 (1–3) 0.097
Pitt bacteremia score (median [IQR]) 3 (1–3) 3 (1–3) 0.845
Genotype (n)d
CC8 (69) 11 (10.2) 58 (43.3) 0.001
CC5 (26) 7 (6.5) 19 (14.2) 0.055
CC22 (20) 20 (18.5) 0 (0) 0.001
CC45 (18) 9 (8.3) 9 (6.7) 0.634
CC30 (15) 8 (7.4) 7 (5.2) 0.484
CC1 (14) 6 (5.6) 8 (6.0) 0.891
CC15 (11) 2 (1.9) 9 (6.7) 0.071
CC88 (11) 11 (10.2) 0 (0) 0.001
CC188 (11) 10 (9.3) 1 (0.7) 0.002
agr type (n)
I (146) 64 (59.3) 82 (61.2) 0.760
II (45) 14 (13.0) 31 (23.1) 0.043
III (48) 29 (26.9) 19 (14.2) 0.014
IV (3) 1 (0.9) 2 (1.5) 0.692
agr dysfunction present 45 (41.7) 79 (59.0) 0.007
Polysaccharide capsule
cap5 42 (38.9) 27 (20.1) 0.001
cap8 64 (59.3) 107 (80.0) 0.001
Antimicrobial resistance gene (antibiotic)
blaZ (penicillin) 84 (77.8) 124 (92.5) 0.002
ermA (erythromycin) 10 (9.3) 63 (47.0) 0.001
aacA-aphD (gentamicin) 3 (2.8) 58 (44.3) 0.001
mupR (mupirocin) 0 (0) 1 (0.8) 0.368
tetK (tetracycline) 2 (1.9) 39 (30.0) 0.001
fosB (fosfomycin) 42 (38.9) 107 (79.9) 0.001
qacA (quaternary ammonia compounds) 12 (11.3) 50 (37.3) 0.001
Leukocidins or exotoxins
PVL 5 (71.4) 2 (28.6) 0.148
tst 7 (46.7) 8 (53.3) 0.870
(Continued on following page)
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(12/45 [26.7%], P  0.001). Of note, agr dysfunction was more
common in the isolates with elevated vancomycin MICs (Table 1,
P  0.007). We also noted that agr dysfunction was present in
55.7% (68/122) of the hospital-onset SAB (P 0.158) and 65.4%
(68/104) of the MRSA (P 0.001) isolates. Among the commonly
encountered clinical presentations, agr dysfunction was associ-
ated with pneumonia (12/14, P 0.008). agr dysfunction was not
associated with 30-day mortality (P 0.662), persistent bactere-
mia (P  0.563), or recurrent bacteremia (P  0.530). agr func-
tion according to each clone is represented in Fig. 3, and agr dys-
function was frequently observed in CC8 (50/69, P 0.001) and
CC30 (15/15, P 0.001). Interestingly, the majority of the CC30
isolates were MSSA (13/15), and agr dysfunction in these isolates
was present in both community- and hospital-onset infections.
Virulence determinants. There was significant heterogeneity
of resistance genes, toxin profiles, and other virulence determi-
nants among the isolates. The frequency of genes encoding Pan-
ton-Valentine leukocidin (lukF/lukS-PV) and staphylococcal
toxic shock syndrome toxin 1 (tst) were low (7/242 and 15/242,
respectively). Selected genes within the most common bacteremia
clones in our cohort are shown in Table 3, and there were some
striking differences between the clones. Capsule type 5 was re-
stricted to CC5 and CC22. These same clones also carried entero-
toxin gene cluster (egc) genes (e.g., seg), which were not seen in
other dominant clones. CC8 contained multiple antimicrobial re-
sistance genes and adhesion factors frequently compared with
other clones, and it accounted for the majority of isolates with the
arginine catabolic mobile element (ACME) locus (18/21), as well
as all of the isolates containing clumping factor A (clfA). However,
compared with the other clones associated with a high vancomy-
cin MIC, hospital-onset bacteremia, or MRSA, CC8 isolates rarely
contained the chemotaxis inhibitory protein (CHIPS). There were
few resistance genes present among the MSSA and MRSA non-
CC8 clones apart from fosB. Although the prevalence of tst was
low, it was almost exclusively linked with CC30 (12/15, P 
0.001). The gene encoding enterotoxin A (sea) was common
among the isolates with a high vancomycin MIC, such as CC8
(50/69) and CC5 (15/26), and it was completely absent among the
isolates with a low vancomycin MIC, such as CC22, CC88, and
CC188. Genes encoding exfoliative toxins, such as etA, were pres-
ent infrequently. agr type II was associated with an elevated van-
comycin MIC (Table 1) and was predominantly found in CC5
(26/45) and CC15 (11/45), whereas agr type III was associated
with a low vancomycin MIC (Table 1) and was predominantly
found in CC1 (14/48) and CC30 (15/48). Although the gene en-
coding serine protease-like protein A (splA) was found in a range
of isolates (Table 3), its presence was associated with elevated
vancomycin MIC (Table 1). The virulence determinants ac-
cording to methicillin susceptibility can be found in Table S1 in
the supplemental material, although our focus was on clonal
origin and vancomycin MICs, irrespective of methicillin sus-
ceptibility, in accordance with the association identified in our
original manuscript (6).
DISCUSSION
Elevated vancomycin MIC is associated with poor outcomes in
MRSA bacteremia (5) and may relate to difficulties in achieving
pharmacodynamic targets. However, the association between el-
evated vancomycin MICs and poor outcome in patients with
MSSA bacteremia in the absence of vancomycin therapy (6, 7) is
more challenging to explain. In this study, we explored the hy-
pothesis that elevated vancomycin MIC may be a signal of or
marker for other intrinsic bacterial characteristics that directly
lead to poor patient outcomes in SAB. Our data support this hy-
pothesis. A high vancomycin MIC in S. aureus (MSSA or MRSA)
predicts infection with particular S. aureus clones that harbor a
specific repertoire of virulence and antibiotic resistance genes, as
well as agr genotypes and phenotypes. The combination of these
TABLE 1 (Continued)
Variablea Low MIC (n 108) Elevated MIC (n 134) P valueb
Enterotoxins
sea 19 (19.4) 79 (80.6) 0.001
seb 11 (10.9) 4 (3.0) 0.015
sec 23 (21.3) 2 (1.5) 0.001
seg 50 (46.7) 40 (30.1) 0.008
Exfoliative toxin etA 2 (1.9) 1 (0.8) 0.435
Adhesion factors
clfA 22 (27.9) 57 (72.2) 0.001
cna 63 (41.2) 90 (58.8) 0.216
Miscellaneous
ACME locus 5 (21.7) 18 (78.3) 0.020
sak 99 (46.1) 116 (53.9) 0.210
CHIPS 61 (57.0) 46 (43.0) 0.001
isaB 68 (54.4) 57 (45.6) 0.002
splA 67 (37.0) 114 (63.0) 0.001
a Data are represented as number (%), unless otherwise indicated. IQR, interquartile range; MRSA, methicillin-resistant S. aureus. DNR, do not resuscitate; ICU, intensive care unit;
APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; ACME, arginine catabolic mobile element; CHIPS, chemotaxis inhibiting
protein of S. aureus.
b P values are uncorrected for multiple analyses (as described in Materials and Methods).
c “Total evaluable” represents the total number of patients for whom the indicated variable was recorded.
d The most common genotypes are recorded. The remaining isolates belonged to CC6 (5), CC7 (2), CC9 (2), CC12 (5), CC20 (6), CC25 (2), CC50 (1), CC59 (3), CC78 (4), CC80
(1), CC93 (3), CC97 (3), CC101 (5), CC361 (2), CC398 (2), unassigned CC on DNA microarray (1; mapped to CC188 on phylogram).
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clone-specific features may be critical in determining clinical out-
comes irrespective of the vancomycin MIC of the isolate and may
explain the observation in high-vancomycin MIC MSSA infec-
tions not treated with vancomycin.
Methicillin resistance was strongly linked with elevated vanco-
mycin MICs, as was demonstrated in a recent meta-analysis (5).
However, within MRSA isolates, there was clonal variation in van-
comycin MICs. MRSA clones with SCCmec type II/III were asso-
FIG 1 Unrooted phylogram of 242 MSSA and MRSA bacteremia isolates and relationship to vancomycin MIC group, onset of SAB, methicillin susceptibility,
and 30-day mortality. CC, clonal complex; ST, sequence type; LA-MSSA, livestock-associated MSSA.
Holmes et al.
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ciated with elevated vancomycin MICs, whereas clones with
SCCmec types IV/V had lower vancomycin MICs, similar to the
results reported by Jang et al. (9). This is consistent with the high
rates of heterogeneous VISA (hVISA) observed in ST239-MRSA-
III, whereas hVISA is less frequent in MRSA harboring SCCmec
types IV/V (9, 27).
CC8 was strongly associated with elevated vancomycin MICs.
It predominantly was found to contain ST239-MRSA-III, a suc-
cessful multiresistant epidemic health care-associated MRSA
clone. Not surprisingly, this clone frequently contained other de-
terminants that may impact vancomycin MIC and mortality, such
as the presence of multiple resistance genes or adhesion factors. As
our CC8 isolates also comprised community-onset S. aureus iso-
lates distinct from hospital-onset ST239-MRSA-III, this also sup-
ports the observations by Miller et al. (28) that CC8 may carry
genetic features supporting its persistence in the community as
well as in the hospital environment. In contrast, CC22 was asso-
ciated with low vancomycin MICs and was almost exclusively
EMRSA-15, an epidemic health care-associated MRSA clone orig-
inally seen in the United Kingdom. Low vancomycin MICs have
been reported in CC22 isolates from the United Kingdom, and
Hope et al. (29) reported no association between vancomycin
Etest MICs and mortality in their MRSA bacteremia cohort. Un-
like Miller et al. (14), we found no CC22 isolates with high vanco-
mycin MICs. Despite the common clonal ancestry of these iso-
lates, the clone itself is clearly not the only factor determining
vancomycin MIC or clinical outcomes and may suggest an addi-
tional effect of geographic adaptation. Interestingly, our CC30
isolates had a much higher median vancomycin MIC than did
those from the Miller cohort (14). Importantly, some CCs had
elevated vancomycin MICs even though they were predominantly
MSSA, for example, CC5, CC6, CC15, and CC20. Different clones
have also been associated with invasive disease, e.g., CC30 and
CC45 (15, 16), and this potentially explains the differences in clin-
ical outcomes and elevated vancomycin MICs.
We confirmed previous findings that agr type II and agr dys-
function were associated with elevated vancomycin MIC and re-
duced vancomycin susceptibility (10, 13, 27), and these have also
been linked to poor outcomes (12). However, the association be-
tween elevated vancomycin MIC and mortality may not necessar-
ily be explained by agr dysfunction alone, as these isolates have
been shown to be less virulent in an invertebrate model (30). The
different clonal backgrounds of isolates within the same agr type
or with agr dysfunction may provide alternative hypotheses. For
example, common clones containing agr type II in our cohort
were CC5 and CC15; both of these clones exhibited a high geo-
FIG 2 Vancomycin Etest MIC according to clonal complex. Black circles indicate geometric mean MICs, boxes indicate interquartile range, error bars represent
range between 10th and 90th percentiles, colored circles represent values outside the 10th to 90th percentiles, and the dotted line indicates vancomycin Etest MIC
of 1.5 mg/liter. The y axis is on a log2 scale. “Other” indicates the remaining clones (n 21): CC7, CC9, CC25, CC50, CC59, CC80, ST93, CC97, CC361, CC398.
CC188 includes one isolate for which a clonal complex was unassigned on microarray but clustered with CC188 on phylogenetic analysis. #, P  0.001 for
comparison of geometric mean MIC for CC8 versus CC22.
TABLE 2 Vancomycin Etest MICs among the common MSSA and
MRSA bacteremia clones in the cohort
CCa
Vancomycin Etest MIC (mg/liter)
Total
Geometric
mean 0.38 0.5 0.75 1 1.5 2 3
8 2.04 2 3 6 40 18 69
15 1.90 2 9 11
6 1.89 1 4 5
5 1.82 1 6 19 26
20 1.70 1 1 4 6
45 1.61 3 6 9 18
1 1.59 1 2 3 8 14
30 1.51 1 3 4 7 15
101 1.35 1 2 2 5
12 1.25 3 1 1 5
88 1.12 8 3 11
188 1.01 1 1 7 1 1 11
22 0.89 1 1 5 11 2 20
a Clones with5 isolates are represented.
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metric mean vancomycin MIC (Table 2) and may possess other
characteristics that contribute to virulence and impact vancomy-
cin susceptibility or clinical outcomes. agr dysfunction was prev-
alent in CC8 and CC30 and was previously reported in other stud-
ies (11, 31). Although these are successful endemic MRSA clones
(32), agr dysfunction also occurred in the community-onset and
MSSA isolates, and this suggests that other features of these geno-
types must contribute to reduced vancomycin susceptibility and
clinical outcomes. Unlike Chong et al. (31), we did not find a
significant proportion of CC5 isolates with agr dysfunction. We
were unable to find an association between agr dysfunction and
persistent bacteremia, as was previously reported (33); however,
this may be due to the low frequency of persistent bacteremia in
our cohort (6.6%).
Isolates containing the sea gene were associated with elevated
vancomycin MICs, whereas those containing egc were associated
with low vancomycin MICs. These findings are similar to those
previously reported, in which the presence of the sea gene was
associated with the severity of infection (34) or invasive disease
(15), and egc was inversely related to septic shock (35). This sug-
gests that reduced vancomycin susceptibility may indeed be a
marker of other organism characteristics that are implicated in
inferior clinical outcomes, even in patients not receiving vanco-
mycin. tst was almost exclusively associated with the CC30 MSSA
isolates, and this was also noted by Blomfeldt et al. (36). Although
clfA has been shown to be important in nasal colonization (37)
and endocarditis (38), the S. aureus isolates in our cohort contain-
ing this gene all belonged to CC8; it is therefore uncertain whether
elevated vancomycin MIC is due to clfA itself or other features of
this clonal complex. The high frequency of ACME carriage in CC8
ST239-MRSA-III (39) may also explain the association between
the ACME locus and elevated vancomycin MIC in our cohort.
splA is essential for dissemination after initial colonization (40)
and was found in the high-vancomycin MIC genotypes CC8 and
CC5; the presence of this gene may be associated with poor clinical
outcomes as a result of metastatic infection.
Antimicrobial resistance genes were frequently associated with
elevated vancomycin MICs. The high prevalence of blaZ is not
unexpected, as S. aureus remains penicillin susceptible in approx-
imately 10% of isolates (4, 41, 42). Although blaZ was statistically
associated with elevated vancomycin MICs, this may reflect the
higher proportion of MRSA among these isolates. Other antimi-
crobial resistance genes, such as ermA, aaC-aphD, tetK, and qacA,
which were also associated with elevated vancomycin MICs, were
found mostly in the CC8 isolates; the association may therefore
reflect the underlying clonal background rather than individual
resistance determinants such as these. Three MRSA isolates did
not have themecA gene detected by microarray; these isolates were
confirmed to be methicillin resistant by susceptibility testing and
belonged to typical MRSA clones (ST239-MRSA-III, EMRSA-15,
and Panton-Valentine leukocidin [PVL]-positive ST93). We do
not know if these isolates lost the mecA cassette or if there is an
alternative explanation, and this is currently under further inves-
tigation and is beyond the scope of this paper. In a study of this
size, it was not practical to test every gene allele for multiple indi-
vidual clinical conditions due to the large number of variables, so
instead, we focused on a smaller number of grouped alleles (as
represented by CC or ST type) and the relationship with vanco-
mycin MIC, an important predictor of clinical outcome. The in-
creasing availability of whole-genome sequencing will allow for
more detailed analysis of the isolates and may help to identify
features of specific clones that lead to an elevated vancomycin
MIC. Significant heterogeneity exists, even within a clonal com-
plex, in organism factors, such as resistance genes and virulence
determinants. It is difficult to ascertain if different genetic or or-
ganism factors directly influence vancomycin MIC, or if an ele-
vated vancomycin MIC is a consequence of various virulence
factors that allow subsequent antibiotic selection pressure. We
believe that an elevated vancomycin MIC may be a proxy for or-
ganism factors that may explain our previous association between
elevated vancomycin MICs and mortality in patients with SAB.
This is particularly relevant, as it highlights the importance of
bacterial factors and potential host-pathogen interactions in de-
termining clinical outcomes, and it may also explain the results
seen in patients with MSSA bacteremia treated with flucloxacillin.
Future clinical trials and research may require considerations of
FIG 3 agr dysfunction (as measured by delta-hemolysin assay) according to clonal complex. n, number of isolates from each CC. CC188 includes one isolate for
which a clonal complex was unassigned on microarray but clustered with CC188 on phylogenetic analysis.
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the clonal origin of S. aureus isolates, especially when trying to
establish the magnitude of treatment effect or assess clinical out-
comes.
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TABLE 3 Comparison of selected genes detected by microarray among the common MSSA and MRSA bacteremia clones in the cohorta
Variableb
Data by clonal complex:
Totalc8 5 22 45 30 1 15 88 188d
No. (%) 69 (35.4) 26 (13.3) 20 (10.3) 18 (9.2) 15 (7.7) 14 (7.2) 11 (5.6) 11 (5.6) 11 (5.6) 195
agr type
I 69 (100) 0 20 (100) 16 (88.9) 0 0 0 0 11 (100) 116
II 0 26 (100) 0 0 0 0 11 (100) 0 0 37
III 0 0 0 0 15 (100) 14 (100) 0 11 (100) 0 40
IV 0 0 0 2 (11.1) 0 0 0 0 0 2
Polysaccharide capsule
cap5 8 (11.6) 26 (100) 20 (100) 0 0 0 0 0 0 54
cap8 61 (88.4) 0 0 17 (94.4) 15 (100) 14 (100) 11 (100) 11 (100) 11 (100) 140
Antimicrobial resistance
blaZ 66 (95.7) 22 (84.6) 19 (95) 14 (77.8) 15 (100) 10 (71.4) 10 (90.9) 10 (90.9) 10 (90.9) 176
mecA 59 (85.5) 6 (23.1) 18 (90) 6 (33.3) 2 (13.3) 4 (28.6) 0 2 (18.2) 0 97
ermA 61 (88.4) 0 0 1 (5.6) 5 (33.3) 0 0 3 (27.3) 0 70
aacC-aphD 58 (84.1) 0 0 0 0 0 0 0 0 58
mupR 1 (1.4) 0 0 0 0 0 0 0 0 1
tetK 34 (49.3) 0 0 5 (27.8) 0 0 0 0 0 39
fosB 69 (100) 26 (100) 0 0 15 (100) 0 11 (100) 1 (9.1) 0 122
qacA 48 (69.6) 3 (11.5) 0 0 0 1 (7.1) 0 5 (45.5) 0 57
Leukocidins or exotoxins
PVL 0 0 0 0 2 (13.3) 1 (7.1) 0 0 1 (9.1) 4
tst 1 (1.4) 2 (7.7) 0 0 12 (80) 0 0 0 0 15
Enterotoxins
sea 50 (72.5) 15 (57.7) 0 0 9 (60.0) 10 (71.4) 0 0 0 84
seb 1 (1.4) 2 (7.7) 2 (10.0) 0 0 1 (7.1) 0 1 (9.1) 1 (9.1) 8
sec 0 0 14 (70.0) 5 (27.8) 1 (6.7) 0 0 5 (45.5) 0 25
sege 2 (2.9) 26 (100) 20 (100) 18 (100) 14 (93.3) 0 0 0 0 80
Exfoliative toxin etA 0 0 0 0 0 0 1 (9.1) 2 (18.2) 0 3
Adhesion factors
clfA 59 (85.5) 0 0 0 0 0 0 0 0 59
cna 61 (88.4) 0 20 (100) 18 (100) 14 (93.3) 14 (100) 0 1 (9.1) 11 (100) 139
Miscellaneous
ACME locus 18 (26.1) 0 3 (15.0) 0 0 0 0 0 0 21
sak 62 (89.9) 25 (96.2) 17 (85.0) 18 (100) 15 (100) 13 (92.9) 1 (9.1) 11 (100) 11 (100) 173
CHIPS 4 (5.8) 17 (65.4) 17 (85.0) 18 (100) 13 (86.7) 0 11 (100) 0 11 (100) 91
isaB 8 (11.6) 26 (100) 0 0 1 (6.7) 14 (100) 11 (100) 11 (100) 11 (100) 82
splA 68 (98.6) 25 (96.2) 0 0 0 14 (100) 11 (100) 11 (100) 11 (100) 140
agr dysfunction presentf 50 (72.5) 8 (30.8) 8 (40.0) 7 (38.9) 15 (100) 8 (57.1) 3 (27.3) 7 (63.6) 5 (45.5) 111
a MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus.
b Data are represented as number (%), unless otherwise indicated. PVL, Panton-Valentine leukocidin; ACME, arginine catabolic mobile element; CHIPS, chemotaxis inhibitory
protein of S. aureus.
c These isolates represent 80.6% of the total tested cohort (195/242 isolates).
d This does not include the isolate for which clonal complex was unassigned on microarray but clustered with CC188 on phylogenetic analysis.
e Part of enterotoxin gene cluster (egc).
f As measured by delta-hemolysin assay.
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